CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
aprepitant +1 moredrug
Likely dose
aprepitant 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01580423
NCT01580423N/ACompleted
CompareCT.gov

The Role of Substance P on Perception of Breathlessness

Dartmouth-Hitchcock Medical Center·interventional·Posted Apr 19, 2012·Updated Jul 19, 2013

In Brief

A clinical study evaluating aprepitant and placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Substance P is released from sensory nerves and transmits pain information into the central nervous system. As pain and dyspnea share many characteristics, including similar neurological pathways, it is possible that substance P may contribute to the sensation of dyspnea. The hypothesis of the study is that patients with chronic obstructive pulmonary disease (COPD) will provide lower ratings of breathlessness during resistive load breathing with oral aprepitant, a medication that blocks the activity of substance P, compared with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 19, 2012
Enrollment StartApr 1, 2012
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.2 years ago

Interventions

aprepitantdrug

125 mg capsule

placebodrug

capsule identical to aprepitant